Who are the top shareholders of the Source Natural?

The top shareholder of Source Natural is Sriveda Sattva Private Limited, owning 74.37% of the shares, followed by public shareholder Guttikonda Vara Lakshmi with 2.96%. Individual investors hold 19.98%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Source Natural include Sriveda Sattva Private Limited, which holds a significant 74.37% of the shares, making it the largest promoter. The highest public shareholder is Guttikonda Vara Lakshmi, who owns 2.96% of the shares. Additionally, individual investors collectively hold 19.98% of the company's shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.

Who are in the management team of Source Natural?

As of March 2023, the management team of Source Natural includes Narayana Narasimhan (Chairman), Arvind Varchaswi N (Managing Director), Tejagna Kashmira Katpitia (Executive Director), and several independent directors: Gowra Srinivas, Chandrakant Laxminarayan Rathi, Sriram Chandrasekaran, and Bharathy. Each member contributes to the company's governance and management.

As of March 2023, the management team of Source Natural includes the following individuals:<BR><BR>1. **Narayana Narasimhan** - Chairman & Non Executive Director<BR>2. **Arvind Varchaswi N** - Managing Director<BR>3. **Tejagna Kashmira Katpitia** - Executive Director & Wholetime Director<BR>4. **Gowra Srinivas** - Independent Director<BR>5. **Chandrakant Laxminarayan Rathi** - Independent Director<BR>6. **Sriram Chandrasekaran** - Independent Director<BR>7. **Bharathy** - Independent Director<BR><BR>Each member plays a significant role in the governance and management of the company.

Has Source Natural declared dividend?

No Dividend History Available

Who are the peers of the Source Natural?

Source Natural's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Bharat Immunolog, Mercury Labs, Makers Labs, Ind-Swift, and Ajooni Biotech. Source Natural has a 1-year return of 105.50%, outperforming its peers, with Divi's Lab showing the highest return at 51.96% and Bharat Immunolog the lowest at -9.01%.

Peers: The peers of Source Natural are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Bharat Immunolog, Mercury Labs, Makers Labs., Ind-Swift, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Source Natural, while Average management risk is found at Mercury Labs. Below Average management risk is noted for Bharat Immunolog, Makers Labs., and Ajooni Biotech, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Source Natural, Divi's Lab., Torrent Pharma, Bharat Immunolog, Mercury Labs, Makers Labs., and Ajooni Biotech, and the rest. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is noted for Source Natural and Torrent Pharma, and Below Average capital structure is observed in Bharat Immunolog, Mercury Labs, Makers Labs., and Ind-Swift.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Bharat Immunolog at -9.01%. Source Natural's 1-year return is 105.50%, which is significantly higher than both. Additionally, the peers with negative six-month returns include Mercury Labs, Bharat Immunolog, and Ind-Swift.

What is the technical trend for Source Natural?

As of June 2, 2025, Source Natural's technical trend is neutral with mixed signals, showing mildly bullish indicators on weekly MACD and Bollinger Bands, but mildly bearish on monthly MACD and daily moving averages.

As of 2 June 2025, the technical trend for Source Natural has changed from mildly bullish to sideways. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a potential upward movement. However, daily moving averages are mildly bearish, indicating short-term weakness. The KST remains bullish on both weekly and monthly, and Dow Theory shows a mildly bullish trend weekly but mildly bearish monthly. Overall, the current technical stance is neutral with moderate strength, driven by conflicting signals from various indicators.

What does Source Natural do?

Source Natural Foods & Herbal Supplements Ltd specializes in allopathic and ayurvedic formulations within the pharmaceuticals and biotechnology sector. As of March 2025, it reported net sales of 161 Cr and a net profit of 6 Cr, with a market cap of INR 100 Cr.

Overview:<BR>Source Natural Foods & Herbal Supplements Ltd operates in the pharmaceuticals and biotechnology industry, focusing on providing allopathic and ayurvedic formulations.<BR><BR>History:<BR>The company was incorporated in 1995 as Inwinex Pharmaceuticals Limited and changed its name to Source Natural Foods & Herbal Supplements Limited in 2011-12. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 161 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 6 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 100 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 33.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.06<BR>- Return on Equity: 14.04%<BR>- Price to Book: 4.71<BR><BR>Contact Details:<BR>Address: 201 2nd Floor Sumeru Towers, 54/46 39 Jayanagar 4th Block Bangaluru Karnataka : 560041 <BR>Tel: 91-80-26087733 <BR>Email: info@source-natural.com <BR>Website: http://www.source-natural.com

How big is Source Natural?

As of 24th July, Source Natural Foods & Herbal Supplements Ltd has a market capitalization of 93.00 Cr, with recent net sales of 44.94 Cr and a net profit of 2.91 Cr. Shareholder's funds are 19.45 Cr, and total assets amount to 23.65 Cr.

As of 24th July, Source Natural Foods & Herbal Supplements Ltd has a market capitalization of 93.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 44.94 Cr and a Net Profit of 2.91 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 19.45 Cr and Total Assets of 23.65 Cr.

Are Source Natural latest results good or bad?

Source Natural Foods & Herbal Supplements reported strong year-on-year sales growth of 87.93%, but faced a 24.70% decline in net sales quarter-on-quarter, raising concerns about sustainability. Analysts have issued a 'Strong Sell' rating, indicating potential challenges ahead.

The latest results for Source Natural Foods & Herbal Supplements present a mixed picture. On one hand, the company reported net sales of Rs 28.17 crore for the quarter ending June 2025, which marks an impressive year-on-year growth of 87.93%. This indicates strong demand for their products and suggests that the company is successfully capturing market interest.<BR><BR>However, when looking at the quarter-on-quarter performance, there are some concerning trends. Net sales decreased by 24.70% compared to the previous quarter, which raises questions about the sustainability of their growth. Additionally, while the standalone net profit showed no change from the previous quarter, it had previously experienced a significant decline.<BR><BR>Moreover, the company's overall performance score has dropped from 15 to 8 over the last three months, indicating challenges in other areas. Analysts have also issued a 'Strong Sell' rating for the stock, reflecting potential concerns about the company's future outlook.<BR><BR>In summary, while Source Natural has demonstrated strong sales growth year-on-year, the recent quarter-on-quarter decline and the drop in performance score suggest that the company may need to address certain challenges to maintain its positive trajectory.

When is the next results date for Source Natural?

The next results date for Source Natural is 14 November 2025.

The next results date for Source Natural is scheduled for 14 November 2025.

Is Source Natural overvalued or undervalued?

As of November 13, 2025, Source Natural is fairly valued with a PE ratio of 29.30 and a PEG ratio of 0.46, indicating reasonable valuation compared to peers, despite a 41.67% decline in stock performance over the past year.

As of 13 November 2025, the valuation grade for Source Natural has moved from attractive to fair, indicating a reassessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 29.30, an EV to EBITDA of 16.59, and a PEG ratio of 0.46. These ratios suggest that while the company has growth potential, its current valuation aligns with its earnings and growth prospects.<BR><BR>In comparison to its peers, Source Natural's valuation appears reasonable. For instance, Sun Pharma has a significantly higher PE ratio of 36.15, while Cipla, considered attractive, has a PE of 22.65. The notable outperformance of Source Natural's PEG ratio at 0.46 compared to peers like Divi's Lab, which has a PEG of 1.99, further supports the conclusion that Source Natural is fairly valued. Additionally, the company's stock has underperformed against the Sensex over the past year, with a decline of 41.67% compared to the Sensex's gain of 8.74%, reinforcing the notion that the stock may not be undervalued at this time.

Should I buy, sell or hold Source Natural?

How has been the historical performance of Source Natural?

Source Natural has demonstrated significant growth in net sales and profitability, with net sales increasing from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, and profit after tax rising from 2.12 Cr to 2.90 Cr during the same period. The company's total assets also grew from 21.45 Cr to 35.83 Cr, indicating a positive trend in financial performance.

Answer:<BR>The historical performance of Source Natural shows a significant upward trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Source Natural's net sales have increased from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, demonstrating robust growth. The total operating income followed a similar trajectory, rising from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25. Operating profit, excluding other income, also saw an increase, reaching 5.15 Cr in Mar'25 from 3.56 Cr in Mar'23. Profit before tax improved from 2.74 Cr in Mar'23 to 3.58 Cr in Mar'25, while profit after tax rose from 2.12 Cr to 2.90 Cr in the same period. The company's earnings per share (EPS) increased from 3.29 in Mar'23 to 4.5 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 21.45 Cr in Mar'23 to 35.83 Cr in Mar'25, alongside total liabilities which increased from 21.45 Cr to 35.83 Cr. The cash flow from operating activities remained stable, with a net cash inflow of 0.00 Cr in Mar'25, while cash and cash equivalents at the end of the period were 7.00 Cr, consistent with the previous year. Overall, Source Natural has shown a positive trend in sales, profitability, and asset growth over the past few years.

Which are the latest news on Source Natural?

Why is Source Natural falling/rising?

As of 04-Dec, Source Natural Foods & Herbal Supplements Ltd's stock price is rising at 138.90, up 4.12% today, primarily due to a significant opening gain. However, despite this short-term recovery, the stock has a year-to-date decline of 28.03% and a concerning drop in investor participation.

As of 04-Dec, Source Natural Foods & Herbal Supplements Ltd is experiencing a rise in its stock price, currently at 138.90, which reflects an increase of 5.5 or 4.12%. This upward movement is primarily attributed to the stock opening with a significant gain of 8.51% today and reaching an intraday high of Rs 144.75. Additionally, the stock has outperformed its sector by 3.83%, indicating a positive performance relative to its peers.<BR><BR>Despite this rise, it is important to note that the stock has shown a decline over longer periods, with a year-to-date drop of 28.03% and a one-year decline of 44.50%. However, the current day's performance suggests a short-term recovery or positive sentiment among investors. The stock's moving averages indicate that it is currently higher than the 5-day and 20-day moving averages, which may also contribute to the positive momentum. <BR><BR>Nevertheless, there is a concerning trend in investor participation, as the delivery volume has decreased by 33.29% compared to the 5-day average, which could indicate a lack of sustained interest from investors. Overall, while the stock is rising today, its longer-term performance remains weak, and the decline in investor participation may pose challenges for future price stability.